Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Spyre Therapeutics, Inc. (NASDAQ:SYRE) ranks 4th on this list.

Following a string of clinical successes in early April, Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock has become a favorite for managers looking to capitalize on the multi-billion dollar Inflammatory Bowel Disease market. A major catalyst for the shares was the recent announcement of Part A induction results from the Phase 2 SKYLINE trial for SPY001. The drug met its primary endpoint in patients with moderate-to-severe ulcerative colitis. The trial showed a 40% clinical remission rate at Week 12, which analysts from Goldman Sachs noted is potentially superior to currently available treatments like Entyvio. The data confirmed a pharmacokinetic profile that could allow for quarterly or even biannual subcutaneous dosing, a massive convenience advantage over the monthly or bi-monthly schedules of competitors.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) has a unique strategy of combining best-in-class antibodies. Beyond SPY001, Spyre is developing long-acting antibodies targeting TL1A and IL-23. Hedge funds believe the real blockbuster potential lies in Spyre’s plan to test these antibodies in combination. Analysts estimate that successful combination therapies could redefine the standard of care in a global IBD market projected to reach $50 billion annually. Given the high efficacy and dosing convenience of its lead assets, many elite money managers view Spyre as a prime acquisition target for Big Pharma players like AbbVie or Takeda looking to defend their IBD franchises.

While we acknowledge the risk and potential of SYRE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SYRE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXTIsrael Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.

Disclosure: None. Follow Insider Monkey on Google News.